Spain
2.1researchedA large, mature, entirely cash-pay market behind two hard structural walls: only individual pharmacists may own a pharmacy, and mail-order dispensing of prescription medicines is explicitly illegal. The workable model, Spain-colegiado doctors prescribing into independent licensed pharmacies, already operates at scale.
- Population
- 48m
- Currency
- EUR
- Region
- Southern Europe
- Updated
- 2026-08-23
The six axes
Five is always better for an operator. Hover a label for the question it answers.
How it works here
Ownership and mail order, the two walls [1][2]
Article 103.4 of the Ley General de Sanidad restricts pharmacy ownership to pharmacists, and Ley 16/1997 makes a pharmacist's personal professional presence an "inexcusable" condition of dispensing. In practice one pharmacist holds one pharmacy. There is no route for outside equity.
On mail order, AEMPS's September 2025 joint notice with EMA and HMA states it directly: "En España los medicamentos sujetos a prescripción médica…no pueden ser comercializados a través de internet." Legitimate online pharmacies appear on the AEMPS/CCAA Distafarma register and carry the EU common logo, for OTC only.
The colegiación requirement [1][2]
Private electronic prescriptions are recognised under Real Decreto 1718/2010, and from July 2025 Spain extended mandatory e-prescription to all medical indications. But multiple legal-content sources state that a prescription issued by a doctor not colegiado in Spain "no constituye prescripción válida para dispensación en farmacia española".
That single requirement is what forces a foreign operator into a Spanish physician network rather than a pan-EU one, and it is why ZAVA runs a Spain-specific storefront rather than serving Spain from its German or Dutch base. Flagged: the specific statutory clause could not be located in RD 1718/2010's text; the requirement is consistent with Spain's general colegiación law but should be confirmed by Spanish counsel.
Reimbursement and pricing [1][2]
Wegovy and Mounjaro for obesity are not reimbursed by the SNS. Ozempic is reimbursed for type 2 diabetes only. Secondary sources report Wegovy prices falling through 2026 and cluster monthly cash costs in the low-to-mid hundreds of euros, but no primary-sourced price list could be verified: treat the numbers you see on comparison sites as indicative.
The oral Wegovy pill is covered by the EU authorisation of 15 July 2026; no Spain launch date has been announced. Orforglipron has no EU approval.
Who is already there
| Name | Model | Price |
|---|---|---|
| ZAVA España | Questionnaire-based online consultation with Spain-registered physicians; patient fills at a pharmacy | n/a |
| mediQuo | Spanish telehealth app with a dedicated "Control de peso" GLP-1 service | ~€30 consultation |
| masendocrino.com | Endocrinology-branded online GLP-1 consultation | n/a |
| Holvia | Madrid-based semaglutide/tirzepatide service with medical supervision branding | n/a |
Routes in, and walls
What works viable
- Build a network of Spain-colegiado physicians for questionnaire-based prescribing and route dispensing through independently owned licensed pharmacies, a marketing and referral partnership, not equity.
What does not blocked
- Any equity in a Spanish pharmacy as a foreign founder or non-pharmacist.
- Mail-order or cross-border dispensing of Rx GLP-1s into Spain. Customs may intercept and administrative proceedings can follow.
- Using non-Spain-registered telehealth doctors for prescriptions intended for Spanish pharmacy fulfilment.
How to make it work
The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.
Physician network for prescribing plus referral partnerships with independently owned pharmacies, and nothing more ambitious than that.
Spain scores zero on both ownership and mail order. Pharmacies are reserved to pharmacists and prescription mail order is closed, so there is no structure that lets you hold the valuable part of the chain. The market is real and the willingness to pay is there, but you would be building a lead-generation business, not a healthcare business.
- Build the colegiado physician networkIt is the only asset you can actually own here.
- Route dispensing through independent pharmacies as a referral relationshipUnderstand exactly what you may and may not be paid for that referral before signing anything.
- Treat this as a traffic play, not an operating playThat may still be the right business, but be honest about which one it is.
You cannot own the pharmacy and you cannot post the medicine, so you are structurally a marketing layer.
Low, and the ceiling is low too.
What has happened
What we could not establish
Kept visible on purpose. These are the gaps a decision would have to close.
- What is the precise statutory basis for the colegiación requirement invalidating foreign telehealth prescriptions?
- What are verified current retail prices per month per dose? No primary price list was obtainable.
- Has AEMPS taken any 2025–2026 enforcement action naming a GLP-1 telehealth or advertising operator, as distinct from general anti-counterfeit campaigns?
On the shared backlog: Can a prescriber in one member state lawfully serve a settled patient population in another as a routine channel, rather than a travelling patient occasionally?
Sources
Every non-obvious claim above links here. Confidence tags are applied strictly.
Read next
Zava
DrEd’s original regulatory arbitrage, rebuilt through Dublin after Brexit and now sitting inside a NYSE-listed issuer alongside its own opposite number.
companyDocMorris
A pharmacy that owns its own prescriber, which is the exact structure §11 ApoG exists to prevent, and it lost on that point in April 2026.
companyYazen
The only operator in this atlas that never touches the drug, and the only one that runs eight countries out of a single Swedish company under Swedish law.
company